RecruitingPhase 1NCT06209619

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

Early, Risk Adapted CC-99282 + Rituximab Post CAR T-Cell Therapy for Non-Hodgkin's Lymphoma

Sponsor

Nathan Denlinger

Enrollment

18 participants

Start Date

Jan 29, 2024

Study Type

INTERVENTIONAL

Conditions

B-Cell Non-Hodgkin Lymphoma-Recurrent

Summary

This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell therapy for non-Hodgkins lymphoma and in whom have had a sub-optimal response early on to CAR T-cell therapy. Immunotherapy with CC-99282 may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving CC-99282 with rituximab may be a safe and effective treatment option for patients who have received CAR-T cell therapy for relapsed or refractory non-Hodgkin's lymphoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests adding two drugs — CC-99282 (a targeted immune drug) and rituximab (an antibody that attacks cancer cells) — shortly after CAR-T cell therapy in patients with B-cell non-Hodgkin's lymphoma. The aim is to boost and sustain the CAR-T cells to improve long-term remission. **You may be eligible if...** - You are 18 or older with B-cell non-Hodgkin's lymphoma (including diffuse large B-cell lymphoma, follicular lymphoma, or related subtypes) - You are planning to receive or have recently received CAR-T cell therapy - You have adequate organ function **You may NOT be eligible if...** - You have Burkitt lymphoma - You have active serious infections or autoimmune conditions - You have received certain prior treatments that would interfere with the study drugs Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBiopsy

Undergo biopsy

PROCEDUREBiospecimen Collection

Undergo blood sample collection

PROCEDUREComputed Tomography

Undergo PET/CT

DRUGGolcadomide

Given PO

PROCEDUREPositron Emission Tomography

Undergo PET/CT

BIOLOGICALRituximab

Given IV

Locations(1)

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06209619

Related Trials

One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL

NCT066183131 location

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT063958702 locations